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Abstract
In tissue engineering, the evaluation of the host response to the biomaterial implantation must 
be assessed to determine the extent of the inflammatory reaction. We studied the degradation 
of poly(butylene succinate) and chitosan in vitro using lipase and lysozyme enzymes, respectively. 
The subcutaneous implantation of the scaffolds was performed to assess tissue response. The 
type of inflammatory cells present in the surrounding tissue, as well as within the scaffold, was 
determined histologically and by immunohistochemistry. In the presence of lipase or lysozyme, 
the water uptake of the scaffolds increased. Based on the weight loss data and scanning electron 
microscopy analysis, the lysozyme combined with lipase had a notable effect on the in vitro 
degradation of the scaffolds. The in vivo implantation showed a normal inflammatory response, 
with presence of neutrophils, in a first stage, and macrophages, lymphocytes, and giant cells in a 
later stage. Vascularization in the surrounding tissue and within the implant increased with time. 
Moreover, the collagen deposition increased with time inside the implant. In vivo, the scaffolds 
maintained the structural integrity. The degradation in vitro was faster and greater compared to 
that observed in vivo within the same time periods.
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Introduction
Many biodegradable polymers have been proposed to produce scaffolds in tissue engineering. 
These structures sustain the extracellular matrix (ECM) production by cells and are expected to 
gradually degrade, allowing the surrounding tissue to replace the supporting function of the scaf-
fold. Biodegradable polymers are used to provide temporary support for cell growth, degrading 
with time, in a controlled way into products, which can be eliminated by regular metabolic path-
ways in the body (biodegradation).1 The biological performance of some biomaterials depends on 
their degradation behavior since this process influences cell performance and inflammatory 
response. Therefore, it is crucial to study the degradation properties of the scaffold for a long-term 
success of the tissue-engineered construct.2
Natural polymers have inherent characteristics that are interesting for specific tissue engineer-
ing applications.3 Chitosan, the partially deacetylated product of chitin, has emerged as one of the 
preferred natural materials, as it is similar to glycosaminoglycans (GAGs), which are native com-
ponents of ECM.4 Additionally, the cationic nature of chitosan allows electrostatic interactions 
with GAGs and proteoglycans.5 In our group, we have been working with chitosan-based scaf-
folds.6–10 One of the most promising biomaterials is Chitosan–poly(butylene succinate (Ch-PBS)) 
processed into scaffolds by melt based technology, combining the biological properties of chitosan 
and the mechanical properties of aliphatic polyesters.6,11,12 Chitosan has been proposed as biomate-
rial for biomedical applications mainly due to its biocompatibility.13,14 Furthermore, it has been 
described as a potent wound healing accelerator,15,16 as well as to modulate the immune system by 
activating macrophages17 to produce cytokines and to inhibit infection.18
PBS is a biodegradable synthetic polymer with good processability when compared to 
poly(lactic acid) or poly(glycolic acid).19 The degradation profile of PBS in the environment has 
been widely studied.20,21 Succinic acid is the main degradation product, which is an intermediate 
of the tricarboxylic acid cycle, that ultimately degrades into carbon dioxide and water.21 Some 
biomaterials are degraded by hydrolysis, being decomposed in contact with water or serum in a 
non regulated way.22 Biodegradation of polymeric biomaterials requires cleavage of hydrolyti-
cally and/or enzymatically sensitive bonds in the polymer.23 Degradation products should be non-
toxic and free of immunogenicity. The resulting products should be small enough to dissolve in 
the body fluids and, after transportation via lymphatic system, the kidneys should be able to 
excrete them from the body.24 The degradation behavior of polymers can be tested in vitro, to 
predict their in vivo behavior when implanted. The biomaterials are usually incubated in phos-
phate-buffered saline, with or without enzymes, at 37°C, under static or agitated conditions to 
simulate the in vivo conditions. It is common that both in vitro and in vivo degradation studies are 
performed in parallel with biocompatibility tests. This is due to the fact that the degradation of a 
biomaterial implant in a host is influenced by the presence and recruitment of inflammatory cells 
as well as by the production of inflammatory mediators.
In vivo, chitosan degrades mainly by the action of lysozyme.25,26 The degradation kinetics of 
chitosan is inversely related to the degree of deacetylation25,27 since this enzyme targets the acety-
lated residues of chitosan polymer.26,28 Human lysozyme is found in several body fluids, including 
serum, tears, saliva, and other fluids, like those surrounding cartilage. During the inflammation 
process, neutrophils and macrophage cells release enzymes, such as lysozyme and reactive oxygen 
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species.29 The degradation of aliphatic polyesters, such as PBS, is known to be catalyzed by 
lipases.30 This enzyme is water-soluble, hydrolyzing ester bonds of triglycerides, phospholipids, 
and cholesteryl esters.31 Human pre-duodenal (lingual and gastric) and extra-duodenal lipase is 
mainly derived from pancreatic cells, but the digestive tract, adipose tissue, lungs, and leukocytes 
also contain lipase.32
An important requisite for clinical application of a biomaterial is its biocompatibility.33 The 
implantation of a biomaterial device sets off a cascade of events starting with acute inflamma-
tion that may lead to a chronic inflammatory response. Polymorphonucleated cells (PMNs), 
macrophages, and new blood vessels are present, and granulation tissue can be developed, with 
subsequent foreign body reaction (FBR) and fibrous capsule development.34 The intensity and 
the duration of the inflammatory reaction are used to characterize the biocompatibility of a 
biomaterial.35 In the case of biodegradable polymers, the intensity of these responses may be 
modulated by the biodegradation process that can cause changes in shape, size, surface rough-
ness, porosity, and release of degradation products.35 Generally, the local reaction of an implant 
is studied after a 3-month implantation period, as described in the ISO 10993-6:1994.36 This 
time frame usually reflects a steady state, where the local acceptance/rejection can be 
evaluated.
In this work, we studied the in vitro biodegradation, as well as the in vivo biocompatibility of 
Ch-PBS fiber mesh scaffolds. The in vitro degradation studies were carried out using lysozyme and 
lipase, in concentrations similar to those present in human blood serum. In vivo studies were per-
formed with the main aim of studying the biodegradation and the biocompatibility of these scaf-
folds, using a subcutaneous model in Wistar rats during 3 months of implantation.
Materials and methods
Scaffolds production
The processing methodology is described in our previous works. Briefly, chitosan (85% deacety-
lated) was melt blended with PBS by extrusion (50 wt%).11 The extrude was ground into powder 
and processed into microfibers (|500 µm) also by extrusion. The fibers (6.5 mm diameter and 1 
mm width) were cut and hot compressed at 150°C for 10 min. The scaffolds were sterilized with 
ethylene oxide for subsequent tests.
In vitro degradation studies
Degradation studies were performed in triplicate by incubating the scaffolds in 10 mL of phosphate-
buffered saline (pH 7.4; control), with lipase from Aspergillus oryzae (Fluka, USA) (110 U/L) and/
or lysozyme from chicken egg white (Sigma, USA) (13 mg/L) at 37°C under agitation (60 r/min) for 
1, 3, 6, and 12 weeks. The enzymatic concentrations used were similar to those found in human 
blood serum. At the end of each degradation period, the samples were removed and immediately 
weighed to determine the water uptake and dried for later calculation of the weight loss.
Water uptake and weight loss determination
Water uptake and weight loss measurements were performed by immersing the scaffolds in phos-
phate-buffered saline or enzymatic solutions at 37°C for up to 12 weeks. The swollen sample 
weights were measured after removing excess surface water by gently touching the surface with 
filter paper. Water uptake was determined from the data on swollen weight (after equilibration and 
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eventual degradation or partial solubilization, ws) and the final dried weight (wf) using equation 
(1). The average of three experiments was considered the water uptake value
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The weight loss was calculated from the initial dried weight wi and final dried weight wf using 
equation (2)
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All samples were weighed before incubation in phosphate-buffered saline or enzymatic solu-
tions (initial weight). After 1, 3, 6, and 12 weeks, three samples of each condition were removed 
and immediately weighed for determination of water uptake (equation (1)), washed thoroughly 
with distilled water, and air dried for later calculation of weight loss (equation (2)).
Analysis of sample morphology by scanning electron microscopy
The morphology of the samples was analyzed after sputter coated with gold by scanning electron 
microscopy (SEM) (NanoSEM; FEI, USA).
In vivo biocompatibility assessment
One day before subcutaneous implantation surgery, the implants were immersed in phosphate-
buffered saline under sterile conditions. In total, 12 adult male Wistar Han rats (41–44 days old at 
the beginning of the experiment), specified pathogen free, were purchased from Charles River 
Laboratories, France. The animals were kept 1 week in a quarantine room and transferred to a 
conventional maintenance room of the experimental unit of the animal facility, where they were 
housed for the full period of the experiment.
At 1, 3, 6, and 12 weeks, samples were retrieved for further analysis. Animals were anesthetized 
by an intraperitoneal injection of a solution of 75/0.5 mg/kg body weight ketamine/medetomidine 
(Imalgene®, Novavet, Portugal/Dorbenvet®, Pfizer, EUA). After confirming the depth of anesthe-
sia by pedal reflex, the dorsum of the animals was shaved and then placed in ventral position. The 
incision site at the dorsal skin was disinfected with chlorhexidine where two medial longitudinal 
incisions were performed. Subcutaneous pockets were created, and four scaffolds were placed in 
each animal, away from the suture site (incision) to avoid inflammation of the wound. The inci-
sions were closed with a 4.0 silk suture (LOOK; Harvard, USA), which was removed 10 days after 
surgery in the animals with longer implantation periods. The anesthesia was then reverted with a 
subcutaneous injection of 0.25 mg/kg Atipamezol (Antisedan®, Novavet, Portugal). When the ani-
mals became active, they were placed in their home cages and water and food were supplied ad 
libitum. Each animal received a subcutaneous injection of 1 mg/kg analgesic Butorphanol 
(Torbugesic®, Pfizer, EUA) administered immediately after surgery and 24 h later, to avoid post-
operative pain. At each time point, animals were euthanized by intraperitoneal injection of sodium 
pentobarbital, at a lethal dose, and the respective implants were retrieved.
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All procedures were conducted in accordance with European regulations for animal laboratory 
testing (European Union Directive 86/609/EEC).
Histological evaluation
Implant processing and hematoxylin and eosin staining
The implants were collected with the surrounding tissues, and histology was performed by fixing the 
implants in 10% neutral buffered formalin. The specimens were cut to obtain 3-µm-thick longitudinal 
and transversal sections to analyze the tissue integration within the scaffolds. Sections were stained 
with hematoxylin and eosin (H&E) to evaluate the cellular infiltration throughout the implants.
Masson’s trichrome staining
Masson’s trichrome stain was used to evaluate the amount and the distribution of mature collagen 
surrounding and within the implants. This stain was used to differentiate collagen from other fibers 
(e.g. smooth muscle and elastin fibers). Masson trichrome stains collagen green, nuclei black and 
cytoplasm red.
Immunohistochemistry
Immunostaining for alpha-smooth muscle actin (D-SMA, Abcam, United Kingdom) antibody was 
performed to assess the vascularization over time. Antigen retrieval was heat induced in a water 
bath at 96°C for 20 min, with incubation of the slides in citrate buffer (pH 6). The slides were 
washed with phosphate-buffered saline, and endogenous peroxidase was blocked with 0.6% hydro-
gen peroxide (H2O2) in methanol at room temperature (RT) for 30 min. R.T.U. VECTASTAIN® 
Universal Elite ABC Kit (VCPK-7200; Vector, United Kingdom) was used for antibody incuba-
tion, according to the instructions of the manufacturer. Sections were incubated overnight in a 
humidified atmosphere with primary antibody (ab5694; Abcam) at 4°C. After washing with phos-
phate-buffered saline, antibody detection was  determined by using the DAB Peroxidase Substrate 
Kit (VCSK-4100; Vector). The slides were washed in water for 5 min and then counterstained with 
Harris’ hematoxylin for nuclear contrast. All images were obtained using an Olympus BX61 
Motorized System Microscope and an attached video camera (Olympus DP70).
Results and discussion
Weight loss and water uptake
The scaffolds based on Ch-PBS were prepared by melt spinning and fiber bonding.11,12 The main aim 
of the in vitro degradation studies was to simulate physiological conditions using enzymes present in 
human serum, which are responsible for the degradation of Ch-PBS fiber mesh scaffolds. Degradation 
with lysozyme and/or lipase was performed under static and agitated conditions. No differences were 
observed by the pH in the different degradation solutions after each incubation time (data not shown).
 The ability of a material to absorb water and its water permeability influence the absorption of 
body fluids and the transfer of cell nutrients and metabolites throughout the materials. The water 
uptake (Figure 1) by the scaffolds immersed in phosphate-buffered saline (control), in dynamic 
conditions without changing the solutions, was approximately 40% hydration. This value is not 
high compared with other chitosan scaffolds,37–39 as the hydrophobic nature of PBS decreases the 
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absorption of water. Previous studies with compact disks of the same polymer blend presented a 
lower value of water uptake,40 which is due to the sample morphology. A fiber mesh structure pre-
sents higher surface area than a compact structure. When only lysozyme was present, the degrada-
tion of the scaffolds was similar to the control (Figure 1). However, the water uptake of the materials 
increased remarkably in the presence of lipase or lipase with lysozyme (Figure 1), which could be 
due to degradation of the scaffolds in the presence of these enzymes.
When analyzing the weight loss profile of the scaffolds in the presence of lysozyme or lipase, 
only a few differences were observed (Figure 2). The degradation of chitosan is mediated by 
lysozyme.25,26 The scaffolds immersed in phosphate-buffered saline supplemented with lysozyme 
presented the highest weight loss (5%) in the first week, as compared with the other conditions. 
The weight loss remained constant until the end of the experiment (Figure 2). The degradation of 
the scaffolds in the presence of lysozyme has similar values to that of the control at the end of the 
experiment. It is well documented in the literature that the degree of deacetylation is inversely 
related to the degradation rate.27,28,41
Lipase enzyme readily hydrolyses ester bonds in polyesters,30,42 and therefore, the weight losses 
obtained were higher than those in the presence of lysozyme and increased with immersion time (Figure 
2). The highest weight loss was observed in the presence of lipase and lysozyme together (Figure 2). 
These results are in agreement with previous studies using different enzymatic mixtures.43,44 The immer-
sion of the scaffolds up to 12 weeks did not cause any lose of structural integrity in the presence of either 
lysozyme (Figure 3(e) and (f)) or lipase (Figure 3(g) and (h)). However, lipase and lysozyme together 
induced loses of structural integrity of the scaffolds after 3 weeks. At the sixth week, all the scaffolds 
lost their structural integrity in the presence of both enzymes (Figure 3(i) and (j)).
Morphology of the scaffolds before and after in vitro degradation
The morphology of the scaffolds was analyzed by SEM, before and after degradation with the dif-
ferent solutions (Figure 3). It was possible to observe the surface of the fibers before degradation 
Figure 1. Water uptake of the scaffolds as a function of immersion time in phosphate-buffered saline with 
lysozyme (13°mg/L), lipase (110°U/L), and both lipase and lysozyme at pH 7.4, temperature of 37°C, under 
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(Figure 3(a) and (b)). After immersion in PBS solution, the surface of the fibers had fissures as a 
result of degradation (Figure 3(c) to (j)) and also a rougher surface (Figure 3(c) and (d)). The scaf-
folds incubated with lysozyme solution (Figure 3(e) and (f)) also presented fissures at the surface 
of the fiber, similarly to those incubated in phosphate-buffered saline. This may be explained by 
the fact that the chitosan used had a high degree of deacetylation causing lysozyme to have mini-
mal effect on the polymer degradation.28 However, for scaffolds incubated in lipase solution 
(Figure 3(g) and (h)), more fissures are visible at the surface of the fibers confirming that lipase 
was attacking the polyester phase. The combination of both lysozyme and lipase (Figure 3(i) and 
(j)), corroborated by the water uptake and weight loss resulted in larger fissures on the surface of 
the fibers.
In vivo biocompatibility assessment by histological analysis
No signs of infection were observed during the study or after surgery. Scaffolds were implanted 
subcutaneously, and explants were retrieved after 1, 3, 6, and 12 weeks. Local tissue integration, 
inflammatory response, and degradation behavior were assessed by histological stains (H&E and 
Masson’s trichrome).
The implantation of a biomaterial may result in injury to tissues or organs.34,45 The tissue response 
to injury depends on various factors, including the extent of the injury, blood–material interactions, 
extent or degree of cellular necrosis, provisional matrix formation, and the inflammatory response.35 
Materials currently used in clinical applications are considered nonimmunogenic, nontoxic, and 
chemically inert and elicit frequently acute and potential chronic inflammatory responses.46
Chitin and chitosan are known to accelerate wound healing and the attainment of a good healing 
surface. Based on histological findings, these substances stimulated the migration of polymorpho-
nuclear and mononuclear cells and accelerated connective tissue regeneration and angiogenesis.47 
It is also known that chitosan has the ability to attract neutrophils and activate macrophages.17,48
Histological analysis of implanted scaffolds revealed that the porous morphology of the 
scaffolds was maintained after 7 days of implantation (Figure 4). The inflammatory infiltrates 
Figure 2. Weight loss of the scaffolds as a function of immersion time in phosphate-buffered saline with 
lysozyme (13°mg/L), lipase (110°U/L), and both lipase and lysozyme at pH 7.4, temperature of 37°C, under 
agitation conditions. Phosphate-buffered saline alone was used as a control.
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Figure 3. SEM micrographs of the morphology of chitosan–poly(butylene succinate) scaffolds (a and b) 
before degradation, (c and d) after 12 weeks in phosphate-buffered saline, (e and f) plus lysozyme, (g and 
h) lipase, and (i and j) both lysozyme and lipase.
SEM: scanning electron microscopy.
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were mainly constituted of neutrophils (Figure 4(b)). These cells were characterized by mul-
tilobulated nuclei, recruited from blood circulation, which reacted to the implanted Ch-PBS 
scaffolds. These cells are characteristic of the acute inflammatory response, which has short 
duration (hours to days), and are characterized by exudation of fluid and plasma proteins 
(edema) and the emigration of leukocytes, mainly neutrophils. The major role of these cells in 
acute inflammatory response is to phagocyte microorganisms and foreign materials. In the 
case of biomaterials, neutrophils are not able to phagocyte them because of the size disparity 
(Figure 4(b)).
At 3 weeks of implantation, the presence of neutrophils was almost gone. The presence of blood 
vessels within the scaffold structure was clear (Figure 4(c) and (d)). The SMA immunostaining was 
visible inside the fibers of the scaffold (Figure 5), which indicated that connective tissue was grow-
ing and vascularization was increasing throughout the scaffold.8
Concurrently, collagen was being deposited by fibroblasts (Figure 6). The appearance of blood 
vessels and fibrosis was an indication of a chronic inflammatory response. This type of response 
emerges when a persistent stimulus is present.
After 6 weeks of implantation (Figure 7(a) and (b)), the evolution of the acute inflammatory 
response into a chronic response was observed by the presence of granulomatous tissue and giant 
cells.
Figure 4. Representative H&E stained histological sections of tissues surrounding chitosan-based implants 
after (a and b) 1 week and (c and d) 3 weeks of subcutaneous implantation in Wistar rats; (b) and (d) 
represent the magnified sections of selected areas (squares) of (a) and (b), respectively. Black arrows point 
to blood vessels.
H&E: hematoxylin and eosin; Ch: chitosan; PBS: poly(butylene succinate).
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Chronic inflammatory response is characterized by the presence of mononuclear cells, which 
includes macrophages, lymphocytes, and plasma cells.49 Implantation of foreign materials elicits 
the foreign body reaction (FBR), composed of foreign body giant cells and granulation tissue 
development, constituted by macrophages, fibroblasts, and capillaries.35 Biodegradable materials 
cause FBR which with time will become chronic until final degradation. In the case of nondegrada-
ble materials, the reaction continues until a capsule is formed around the implant, isolating it and 
FBR from the local tissue environment.46 Foreign body giant cells are formed when material parti-
cles are too large to be phagocyted by macrophages and these cells fuse. In Figure 5(c), the phago-
cytosis of a chitosan particle by giant cells is observable (dashed arrow). A major organization of 
the tissue within the implant was observed with a marked presence of D-SMA (Figure 5(c)) and 
collagen deposition (Figure 6(c)).
At the end of the 12th week, organized tissue around and within the implanted scaffold was 
observed (Figure 7(c) and (d)) with collagen deposition (Figure 6(d)), adipocytes (Figure 7(c) and 
(d)), and a substantial increase in vascularization of the neo-formed tissue (Figure 6(d)). Moreover, 
it was visible that cells started to colonize the interior of the fibers (Figure 7(c) and (d)), which 
means that polymers were being degraded. Additionally, more blood vessels were present (Figure 
6(c)), and some adipocytes (Figure 6(d)) in the surroundings of the implantation site were observed.
Up to 3 months, there were no signs of significant degradation of the implanted scaffolds (Figure 
8). Histological findings only revealed the ingrowth of cells within each fiber of the scaffold 
Figure 5. Representative D-SMA immunostained sections of tissues inside fibers of Ch-PBS mesh scaffolds 
after (b) 3 weeks, (c) 6 weeks, and (d) 12 weeks of implantation. (a) Negative control. Black arrows point 
to new blood vessels. Dashed arrow points to a phagocyted chitosan particle.
Ch: chitosan; PBS: poly(butylene succinate); SMA: smooth muscle actin.
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(Figure 7(c) and (d)). There was some evidence that giant cells attempted to phagocyte the particles 
of the scaffold (Figure 7(c)).
After 12 weeks of implantation, all scaffolds maintained their shape and structure (Figure 8), in 
contrast with the in vitro results, in which after 6 weeks of incubation in lipase and lysozyme, the 
scaffolds lost their structural integrity (Figure 2). Thus, it is clear that in vitro degradation was 
much faster than in vivo degradation. One fact that must be highlighted is that the magnitude of 
tissue response to a biodegradable material depends upon the site of implantation.50 It was our aim 
to mimic the in vivo environment with enzymes that are present in the human body and are specific 
for the degradation of chitosan and the polyester. However, the in vivo results were not similar to 
those of in vitro, and this can be explained based on the activity of the enzymes. Another issue is 
the type of the enzymes used, which even at concentrations similar to the ones in human serum are 
not from human origin and their action might be slightly different. Furthermore, in vitro tests pro-
vide a much more hydrated environment than the host environment in vivo.
Conclusion
The degradation rate of the scaffolds must be tailored appropriately accordingly with the growth 
rate of the new tissue. The enzymatic mixture with lysozyme and lipase had a strong positive effect 
on the scaffolds degradation. The in vitro degradation studies were carried out using lysozyme and 
lipase, in concentrations similar to those present in human blood serum. After 12 weeks of in vivo 
Figure 6. Masson’s trichrome stained sections of tissues of chitosan–poly(butylene succinate) mesh 
scaffolds after (a) 1 week, (b) 3 weeks, (c) 6 weeks, and (d) 12 weeks of implantation. Green stain is 
collagen. The bar corresponds to 500 µm.
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Figure 7. Representative H&E stained histological sections of tissues surrounding chitosan-based implants 
after (a and b) 6 weeks and (c and d) 12 weeks of subcutaneous implantation in Wistar rats; (b) and (d) 
represent the magnified sections of selected areas (square) of (a) and (b), respectively. Black arrows point 
to new blood vessels.
H&E: hematoxylin and eosin; Ch: chitosan.
Figure 8. (a and b) SEM micrographs of chitosan–poly(butylene succinate) scaffolds after 12 weeks of in 
vivo implantation.
SEM: scanning electron microscopy.
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implantation, the structural integrity of the scaffolds was retained. It should be noted the difference 
in kinetics of biodegradation in vitro and in vivo. The implanted scaffolds displayed a normal to 
mild tissue response, with the development of chronic inflammatory response and FBR.
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